In order to thrive, you need to have all of the tools at your fingertips, and that includes evidence-based therapies that go beyond conventional oncology.
Download our FREE PDF guide filled with evidence-based therapies that you can start today to manage your Pancreatic Cancer. Click the orange button to get your download now.
A diagnosis of advanced pancreatic cancer is tough. Only because conventional oncology has little to offer pancreatic cancer patients. I keep an eye out for outside the box thinking for incurable cancers because patients and caregivers often tell me that “they will do anything to treat their cancer.” Or something to that effect.
Keep in mind that my own cancer was also considered incurable by conventional oncology. I failed aggressive chemo and radiation. Back in 1997.
For a while now I have been co-workers with a pancreatic cancer survivor named Connie. Connie was diagnosed about three years ago. Good length of survival but not great… yet. The reason why I am talking about Connie is because she is in complete remission from her pancreatic cancer.
By undergoing local radiation Connie figured out how to shrink her PC tumor enough to become eligible for the Wipple Procedure.
In addition to conventional therapies such as local radiation and surgery, pancreatic cancer patients can add an evidence-based but non-conventional therapy- curcumin. Curcumin has been shown to kill pancreatic cancer.
For more information about managing your cancer- be it with conventional or non-conventional therapies scroll down the page, post a question or comment and I will reply ASAP.
“Among common cancers, pancreatic cancer has one of the poorest prognoses. Because pancreatic cancer often grows and spreads long before it causes any symptoms, only about 6% of patients are still alive five years after diagnosis…
For some pancreatic patients, however, a complex surgery known as the Whipple procedure may extend life and could be a potential cure. Those who undergo a successful Whipple procedure may have a five-year survival rate of up to 25%…
Only about 20% of pancreatic cancer patients are eligible for the Whipple procedure and other surgeries. These are usually patients whose tumors are confined to the head of the pancreas and haven’t spread into any nearby major blood vessels, the liver, lungs, or abdominal cavity. Intensive testing is usually necessary to identify possible candidates for the Whipple procedure…
It’s not yet known if therapy works better before or after surgery. But some research suggests that therapy could allow a few patients who are initially thought to be ineligible for surgery to eventually undergo the Whipple procedure. Studies are ongoing…
Purpose: Pancreatic cancer is almost always lethal, and the only U.S. Food and Drug Administration-approved therapies for it, gemcitabine and erlotinib, produce objective responses in <10% of patients. We evaluated the clinical biological effects of curcumin (diferuloylmethane), a plant-derived dietary ingredient with potent nuclear factor-kappaB (NF-kappaB) and tumor inhibitory properties, against advanced pancreatic cancer…
Results: Twenty-five patients were enrolled, with 21 evaluable for response. Circulating curcumin was detectable as drug in glucuronide and sulfate conjugate forms, albeit at low steady-state levels, suggesting poor oral bioavailability.
Two patients showed clinical biological activity. One had ongoing stable disease for >18 months; interestingly, one additional patient had a brief, but marked, tumor regression (73%) accompanied by significant increases (4- to 35-fold) in serum cytokine levels (IL-6, IL-8, IL-10, and IL-1 receptor antagonists).
No toxicities were observed. Curcumin down-regulated expression of NF-kappaB, cyclooxygenase-2, and phosphorylated signal transducer and activator of transcription 3 in peripheral blood mononuclear cells from patients (most of whom had baseline levels considerably higher than those found in healthy volunteers). Whereas there was considerable interpatient variation in plasma curcumin levels, drug levels peaked at 22 to 41 ng/mL and remained relatively constant over the first 4 weeks.
Conclusions: Oral curcumin is well tolerated and, despite its limited absorption, has biological activity in some patients with pancreatic cancer.